Abnormal CSF monoamine metabolism in serotonin syndrome [6]

Journal of Clinical Psychopharmacology

Volumn 23, Issue 5, 2003, Pages 528-531

  Nisijima, Koichi ^a   Nibuya, Masashi ^a   Sugiyama, Hisashi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CLOMIPRAMINE; FLUVOXAMINE; HOMOVANILLIC ACID; IMIPRAMINE; NORADRENALIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; DEPRESSION; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; HUMAN; LETTER; MALE; MONOAMINE METABOLISM; PRIORITY JOURNAL; SEROTONIN SYNDROME;

ADULT; AGED; BIOGENIC MONOAMINES; FEMALE; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MIDDLE AGED; SEROTONIN SYNDROME; STATISTICS, NONPARAMETRIC;

EID: 0141593898     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000088920.02635.5a     Document Type: Letter

References (16)

1. Mills KC. Serotonin syndrome. Crit Care Clin. 1997;13:763-783.
2. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.
3. Nisijima K. Abnormal monoamine metabolism in cerebrospinal fluid in a case of serotonin syndrome. J Clin Psychopharmacol. 2000;20:107-108.
4. Nisijima K, Nibuya M, Kato S. Toxic serotonin syndrome successfully treated with electroconvulsive therapy. J Clin Psychopharmacol. 2002;22:338-339.
5. Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res. 1995;29:233-244.
6. Geracioti TD, Loosen PT, Ekhator NN, et al. Uncoupling of serotonergic and noradrenergic systems in depression: preliminary evidence from continuous cerebrospinal fluid sampling. Depress Anxiety. 1997;6:89-94.
7. Gjerris A, Werdelin L, Rafaelsen OJ, et al. CSF dopamine increased in depression: CSF dopamine, noradrenaline and their metabolites in depressed patients and in controls. J Affect Disord. 1987;13:279-286.
8. Post RM, Lake CR, Jimerson DC, et al. Cerebrospinal fluid norepinephrine in affective illness. Am J Psychiatry. 1978;135:907-912.
9. Veith RC, Lewis N, Langohr JI, et al. Effect of desipramine on cerebrospinal fluid concentrations of corticotrophin-releasing factor in human subjects. Psychiatr Res. 1993;46:1-8.
10. Adams RD, Victor M. Disorder of the autonomic nervous system, In: Principles of Neurology. 5th ed. New York: McGraw-Hill; 1993:457-479.
11. Ziegler MC, Lake CR, Wood JH, et al. Norepinephrine in cerebrospinal fluid-basic studies, effects of drugs and disease. In: Wood JH, ed. Neurobiology of Cerebrospinal Fluid 1. New York: Plenum, 1982:141-152.
12. Done CJG, Sharp T. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology. 1994;33:411-421.
13. Pacák K, Palkovits M, Kvetnanský R, et al. Effects of various stressors on in vivo norepinephrine release in the hypothalamic paraventricular nucleus and on the pituitary-adrenocortical axis. Ann N Y Acad Sci. 1995;771:115-130.
14. Fink M. Toxic serotonin syndrome or neuroleptic malignant syndrome? Case report. Pharmacopsychiatry. 1996;39:159-161.
15. Cremniter D, Jamain S, Kollenbach K, et al. CSF 5-HIAA levels are lower in impulsive as compared with nonimpulsive violent suicide attempters and control subjects. Biol Psychiatry. 1999;45:1572-1579.
16. Placidi GP, Oquendo MA, Malone KM, et al. Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biol Psychiatry. 2001;50:783-791.